The Valley Desk

NCT06789913 · Interventional trial

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

Overall registry status Recruiting

Phase 2

Conditions CLOVES Syndrome, Klippel Trenaunay Syndrome, Lymphatic Malformations, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP), PIK3CA Mutation, PIK3CA-Related Overgrowth Spectrum (PROS), Vascular Anomalies, Vascular Malformations

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov